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Ramirez-Zamora et al. Seventh Annual DBS Think Tank
The Seventh Annual Deep Brain Stimulation (DBS) Think Tank held on September 8th
of 2019 addressed the most current: (1) use and utility of complex neurophysiological
signals for development of adaptive neurostimulation to improve clinical outcomes;
(2) Advancements in recent neuromodulation techniques to treat neuropsychiatric
disorders; (3) New developments in optogenetics and DBS; (4) The use of augmented
Virtual reality (VR) and neuromodulation; (5) commercially available technologies; and
(6) ethical issues arising in and from research and use of DBS. These advances serve
as both “markers of progress” and challenges and opportunities for ongoing address,
engagement, and deliberation as we move to improve the functional capabilities and
translational value of DBS. It is in this light that these proceedings are presented to
inform the field and initiate ongoing discourse. As consistent with the intent, and spirit
of this, and prior DBS Think Tanks, the overarching goal is to continue to develop
multidisciplinary collaborations to rapidly advance the field and ultimately improve
patient outcomes.
Keywords: deep brain stimulation, stereoelectroencephalography, depression, Parkinson’s disease, tremor,
optogenetics, local field potentials, neuroethics
INTRODUCTION
Since 2012, the annual Deep Brain Stimulation (DBS) think
tanks have convened subject matter experts in neuromodulation
research and clinical practice to exchange ideas, discuss
developing technologies, address and plan for current and
future challenges and opportunities in the field (Gunduz
et al., 2015; Deeb et al., 2016; Rossi et al., 2016; Ramirez-
Zamora et al., 2018, 2019). The Seventh Annual DBS Think
Tank took place on September 8, 2019 (a virtual meeting
held via Zoom Video Communications inc due to travel
concerns and impediments caused by Hurricane Dorian). The
meeting focused on advances in: (1) commercially available
technologies; (2) the use of advanced technologies to improve
clinical outcomes; (3) research in neuromodulatory approaches
to treating neuropsychiatric disorders; (4) the use and utility
of complex neurophysiological signals for advancing delivery
of neurostimulation; and (5) ethical issues arising in and from
research and use of DBS.
APPLYING ADVANCED
NEUROPHYSIOLOGICAL SIGNALS TO
ADVANCE DBS TREATMENT
Adaptive Deep Brain Stimulation in
Parkinson’s Disease
Adaptive deep brain stimulation (aDBS) for movement disorders
has been demonstrated to be effective during in-clinic, short
term testing. Early studies suggested that beta activity may be
a reasonable biomarker for PD clinical state (Kühn et al., 2006;
Little et al., 2012a,b). aDBS uses unique neurophysiological
signals to direct the delivery of stimulation to control motor
symptoms (Supplementary Figure S1). The first human
trials of aDBS used a subcortical beta signal and a fixed
threshold with short time scales (Little et al., 2013, 2016a,b).
This protocol targeted prolonged beta bursts and, through
stimulation, shortened their duration (Tinkhauser et al.,
2017a,b). The initial studies found that aDBS was more effective
than conventional (cDBS) using blinded Unified Parkinson’s
Disease Rating Scale (UPDRS) ratings (both unilaterally and
bilaterally). Moreover, aDBS reduced speech side effects (acutely)
and was appropriately responsive to levodopa medication
(Little et al., 2016b). This approach has subsequently been
shown to possibly prevent dyskinesia (Rosa et al., 2015;
Arlotti et al., 2018).
The initial limitations of early studies were the post-operative
microlesion effect and the brevity of stimulation. One
post-operative study did however successfully stimulate
for 8 h across medication cycles (Arlotti et al., 2018).
Other studies have attempted to implement aDBS in
the chronic phase, at battery change or in chronically
implanted systems, and have shown aDBS to be as effective
as cDBS, despite significantly reduced current delivery (Piña-
Fuentes et al., 2017, 2019a; Velisar et al., 2019). Additional
signals are being investigated, and dyskinesia has been
associated with a narrowband gamma oscillation in the
motor cortex between 60 and 90 Hz, with a similar but
weaker oscillation in the subthalamic nucleus (STN) and
strong phase coherence between the two (Swann et al., 2016).
Successful control of hyperkinetic movements using an adaptive
DBS design has been conducted with encouraging results
(Swann et al., 2018b).
Notable was the use of a dual-threshold system and
kinematic evaluation in a chronic fully implanted beta
aDBS system. This approach was shown to be feasible and
of practical utility in clinical settings (Velisar et al., 2019;
Supplementary Figure S2). Direct kinematic assessments
may be important for advancing aDBS and for preventing
deleterious effects (although it remains to be determined if
and to what extent small kinematic differences will impact
clinical outcomes; Johnson et al., 2016). To date, there
have been eight trials of aDBS in PD, and all trials have
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shown aDBS to be at least equivalent to cDBS in achieving
relevant clinical outcomes. Ascertainment of whether this
approach will be equivalently more effective in out-of-
clinic (i.e., real-world) environments will require larger
trials using fully implanted devices with embedded sensing
capabilities. The use of aDBS for treating other conditions,
including tremor and dystonia, has only begun to be tested,
and initial findings suggest that this approach could be
promising for treating these conditions. As well, the use
of patterned stimulation using the neural activity phase
rather than just local field potentials (LFP) amplitude is
being considered (Cagnan et al., 2014, 2017; Piña-Fuentes
et al., 2019b). It is unclear if aDBS would provide a clear
advantage in reducing the burden and complexities of prolonged
programming visits as additional time might be required to
set up appropriate stimulation. This is an important but as
yet unanswered question that remains the focus of future
research. Overall, these studies provide a building body of
support for the use and value of aDBS in treating a number of
movement disorders.
Sensing and Adaptive Loop Stimulation
Using the Summit RC+S Platform: Early
Experience
Chronically implantable neuromodulating devices that both
sense brain activity and deliver stimulation (i.e., ‘‘bidirectional’’
interfaces) have generated excitement in the neurosurgical and
neurology communities. Potential uses of bidirectional interfaces
include the identification of electrophysiologic signatures of
specific signs or symptoms of brain disorders, and the
development of aDBS (Modolo et al., 2012; Swann et al.,
2018b). However, the first-generation devices (that have
been available since 2013) had limitations in signal quality,
management of stimulation artifact, and the capability for
continuous collection of brain data in home environments
(Swann et al., 2018a). Toward closing these gaps, we have
gained experience with a newly available second-generation
device, Summit RC+S (Medtronic) in five patients with PD
(Stanslaski et al., 2018). In our recent protocol, the Summit
RC+S DBS was attached to a quadripolar depth lead (STN
or Globus Pallidus Interna (GPi); for both stimulation and
sensing), and a quadripolar paddle lead in the subdural space
over the primary motor cortex (for sensing only). While this
system was more customizable than previously used devices, the
relative complexity of RC+S system necessitated a team approach
to include software engineers to customize programs using
the device application-programming interface (API). Summit
RC+S provided substantial improvements over first-generation
devices with respect to signal to noise characteristics, long term
continuous data streaming, and interference from stimulation or
other artifacts. These features permitted hundreds of hours of
recording of electrophysiologic data that could be obtained in
the home environment. Additionally, RC+S-obtained data can
be synchronized offline to pair with external wearable sensors
(such as smartwatches) to further characterize physiologic states.
Our initial results showed canonical levodopa-related changes
in subthalamic and cortical field potentials that have previously
been demonstrated only using externalized leads in brief in-clinic
recording periods. The use of LFP electrophysiologic signatures
and classifiers made it possible to distinguish clinical states
with high accuracy in out-of-clinic (i.e., home) environments
(Supplementary Figure S3). We view this as a critical step in
advancing aDBS toward a more useful therapy. Moreover, the
capability for invasive neural recording over long periods of
time in naturalistic environments will afford a novel method
for acquiring basic neuroscientific data that can be used to
guide subsequent bio-engineering and clinically relevant research
directions and developments.
Combining Directional DBS and Physiology
Toward an Adaptive Loop Approach
aDBS and directional DBS (dDBS) are two recent technological
innovations that have fostered new strategies to refine the
DBS programming process (Modolo et al., 2012; Kühn and
Volkmann, 2017). aDBS is a technique in which DBS output
incorporates real-time sensing data via a feedback mechanism
in order to guide stimulation delivery. dDBS refers to DBS
leads with segmented electrodes that enable the generation of
a spatially selective electric field directed toward a brain region
of interest. These methods contrast with cDBS, which utilizes
a ring-shaped electrode that can only generate electric fields
symmetric about the long axis of the lead. Both aDBS and dDBS
have been important to developing DBS optimization strategies
that focus both on temporal domains (utilizing aDBS), and
spatial domains (using dDBS). Studies of dDBS have reported
that although DBS programming time can significantly increase
with this new approach, there is also potential expansion of the
therapeutic window (Contarino et al., 2014; Pollo et al., 2014;
Steigerwald et al., 2016; Dembek et al., 2017; Rebelo et al., 2018;
Ten Brinke et al., 2018).
LFP recordings from basal ganglia in PD patients using
dDBS technology have indicated that beta signal strength
is not homogenously distributed around segmented leads
(Fernández-García et al., 2017; Tinkhauser et al., 2018).
Selective stimulation of these regions with high beta power was
associated with greater therapeutic benefit (Tinkhauser et al.,
2018) and could serve as a physiology-based tool to optimize
DBS contact selection. As technology continues to improve,
combining dDBS with aDBS may afford improved clinical
outcomes due to a wider therapeutic window, a more flexible
selection of stimulation and recording contacts, and improved
DBS programming time through the utilization of automated
aDBS techniques.
DBS Local Evoked Potentials: The ERNA
STN DBS for treatment of PD requires precise lead placement
but marked variability between lead location among patients
might cause difficulties optimizing stimulation parameters. The
burden of programming has been increasing with the advent
of current steering electrodes, and this technology has also
increased the available parameter space. The use of a neuronal
biomarker to guide electrode implantation could be beneficial
for performing surgery, particularly if the patient is asleep. Such
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a biomarker could guide stimulation in at least two domains:
parameter settings and adaptive control. The biomarker should
localize to the STN, reflect the clinical state of the patient,
modulate with DBS, possess reasonably fast correlation, and be
reliably detectable.
Currently, beta oscillations are a commonly used biomarker
metric (Wingeier et al., 2006; Little et al., 2013; Tinkhauser
et al., 2018). However, these oscillations are small (<15 µV),
and can be difficult to detect in and across certain conditions.
In this light, we propose a new biomarker, evoked resonant
neural activity (ERNA), which is significantly larger than the
beta band (>100 µV) and can be reliably recorded across all
conditions (Sinclair et al., 2018, 2019). ERNA is evoked and
recorded from within the STN itself and is generated by a train of
square biphasic pulses. After cessation of the pulses, the evoked
response persists with a decaying oscillation. Both the amplitude
and frequency seem to be components of the biomarker.
Unlike beta oscillations, ERNA is an active signal created by
stimulation, and cannot be recorded from resting-state activity.
ERNA localizes to the STN (Supplementary Figure S4A) and is
present under general anesthesia (Supplementary Figure S4D),
suggesting a role to guide electrode implantation with patients
asleep without intraoperative imaging (Sinclair et al., 2018).
ERNA amplitude varies even within the STN, being maximal
in the dorsal subregion where DBS is reported to achieve
the greatest benefit (Horn et al., 2017; Sinclair et al., 2018;
Supplementary Figure S4B) and electrodes that record larger
ERNA amplitudes have been found to produce greater clinical
benefit (Supplementary Figure S4C). These findings raise the
possibility that the ERNA amplitude could help guide electrode
contact selection. Moreover, the frequency of ERNA modulates
during DBS (Supplementary Figure S4E), reducing on average
from around 310 Hz pre-therapy to around 260 Hz when
therapy reaches clinically effective levels (Sinclair et al., 2019).
It is intriguing that the latter value is around twice the
commonly employed applied STN DBS frequency of 130 Hz,
though it is crucial to note that the plateau frequency that
ERNA reaches with therapeutic DBS differs between individuals.
Future work will assess whether the plateau frequency that
ERNA reaches with therapeutic DBS could inform on the
ideal DBS frequency to apply in individuals. During DBS,
modulation of ERNA frequency correlates with the amplitude
of beta oscillations (a useful surrogate of the clinical state of
the patient; Supplementary Figure S4F; Sinclair et al., 2019).
During programming, the ERNA could facilitate optimization
of more precise settings, especially given that there is a larger
amplitude in the dorsal motor region of the STN (Sinclair
et al., 2018). This raises the possibility that ERNA frequency
could be investigated as a biomarker to trigger adaptive STN
DBS in PD.
Multimodal Evoked Potential Elicited by
DBS: New Candidate Biomarkers to Guide
Novel Therapies
Optimal DBS therapy is challenged by complex new technologies
and heterogeneous diseases, leading to two important
questions. Which biomarkers are the most suitable, and
where should one record? Multimodal recordings of stimulus-
evoked activity elicited by DBS paired-pulse studies leverage
electroencephalography (EEG), electrocorticography (ECoG),
and DBS LFP data. Data from these recordings can be used
to help answer these questions. Our group recorded EEG
potentials from STN (i.e., in PD) and thalamic (i.e., in
essential tremor) neurons during therapeutic stimulation.
Stimulation generated a polyphasic event-related potential
in the ipsilateral sensorimotor cortex, with peaks at discrete
latencies beginning less than 1 ms after stimulus onset (Walker
et al., 2012a,b). There are marked differences in evoked
potential (EP) morphology between effective and ineffective
stimulation, with high-frequency activity occurring after
ineffective stimulation. Avoiding capsular side effects (elicited
by stimulating the surrounding internal capsule) can also be
important when recording.
We also evaluated ECoG responses recorded from the
primary motor cortex, following paired-pulse stimulation. As
the interstimulus interval between the conditioning stimulus
(CS) and the testing stimulus (TS) diminished, the latency
increased and amplitude decreased, and the evoked response
disappeared entirely as the interval fell below 1 ms. These
effects highlight the relative and absolute refractory periods
of neurons. DBS LFP recordings stimulate from the two
inferior contacts and record from the two superior contacts
of the depth lead. They show a response with a latency of
350 µs, as well as ERNA (Sinclair et al., 2018). As the CS
and TS approach become more proximate, there is evidence
of relative and absolute refractory periods as the latency
increases and amplitude decreases, with the evoked response
and ERNA disappearing as the two stimuli converge. With
trains of stimulation, the ERNA shows remarkable facilitation
at 500 Hz and at the clinically relevant frequencies of
100–250 Hz.
When co-recorded, EEG, ECoG, andDBS LFPs show latencies
of 1 ms, 1 ms, and 350 µs, respectively, with each modality
showing an increasing amplitude of the response by an order of
magnitude when measured from scalp to subcortical recordings.
All modalities show relative and absolute refractory periods
consistent with the activation of neural structures. These
responses were consistently observed across all modalities. In a
recent report, our group presented evidence that DBS-evoked
responses, including those at extremely short latencies, have
a neural origin beneath or very near the ECoG strip over
the ipsilateral premotor and motor cortex (Awad et al., 2020).
It is proposed that the most likely underlying mechanism
responsible is non-synaptic, retrograde activation of cortical
neurons whose axons project to the subcortical stimulation
site. Other factors might impact the spatiotemporal patterns
of cortical activation by DBS and additional computation and
basic science experiments should focus on a comprehensive,
systems-level and physiological understanding of DBS. Relevant
discussion at the time of the meeting questioned the use of this
technique in clinical practice. At the present time, no clinical
decisions are made by the University of Alabama team using
this research protocol. Parameters are selected based on the
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most effective clinical response intraoperatively using a bipolar
configuration with standard STN pulse width and frequencies.
Neuronal Sources of Evoked Potentials
SNT DBS produces EPs both locally (i.e., in STN; sEP) and in
the cortex (cEP). EPs can be regarded as a possible biomarker of
neural responses to stimulation, but the origin of EP activity is
not wholly clear. To address this issue, we used computational
models to better understand the neural elements involved
in—and contributing to—EPs.
The cEP included short-latency positive (P1), intermediate
latency negative (N1), and long-latency positive (P2) responses
in the rat (Kumaravelu et al., 2018) and human models
(Walker et al., 2012a). Using a computational model of the
thalamocortical (TC) network (Traub et al., 2005) to decipher
the origin of cEPs (Kumaravelu et al., 2018), DBS was
simulated by activating layer 5 pyramidal axons (antidromically)
and applying inhibitory postsynaptic current to the thalamus
(orthodromically), thereby mimicking hyper direct and indirect
pathway activation, respectively. Model-based cEPs matched
well with cEPs obtained from both rats and humans. P1 and
N1 responses were due to the direct and recurrent activation
of L5 pyramidal neurons, respectively, while P2 responses
arose from polysynaptic activation of L2/3 pyramidal neurons
following a cortico-thalamocortical loop. Antidromic activation
alone can faithfully reproduce cEPs. Understanding anatomical
pathways of cortical modulation can be used to optimize
therapeutic targets, and cEPs may aid in electrode placement,
selection of stimulation parameters, and/or in adaptive (closed)-
loop control.
Unlike thalamic DBS EPps (Kent et al., 2015), sEPs were
polyphasic and highly stereotyped (Grill et al., 2015; Sinclair
et al., 2018). Implementing a 3-dimensional biophysical model
of the STN-GPe subcircuit enabled the determination of the
origin of sEPs. Model-generated sEPs for 45 Hz and 130 Hz
DBS were similar to sEPs from humans with PD, indicating
the involvement of STN-GPe interactions and hyper direct
axons. The early positive phase resulted from antidromic STN
excitation, while the early negative phase reflected strong
inhibition by local pallidal terminals. The high-frequency
oscillations occurring after the DBS pulse were caused by quasi-
periodic pallidal inhibition. As with cEPs, sEPs reveal functional
connectivity, andmay also be useful as a guide for lead placement
or as signals for adaptive-loop control.
ADVANCEMENTS IN RECENT
TECHNIQUES IN NEUROMODULATION:
EMERGING BRAIN TARGETS, USE OF
MULTIPLE LEADS AND
STEREOELECTROENCEPHALOGRAPHY
(SEEG)
Emerging DBS Targets in Non-motor
Disorders
As the number of refereed publications reflects, the field
and use of DBS have increased from the late 1990s to the
present, as evidenced by less than 100 published papers to
over 1,000 papers published per year (Lee et al., 2019). To
characterize this growth and to describe the state of the
field, a comprehensive overview was presented through data
obtained using ClinicalTrials.gov. At the time of this Think
Tank, there were 422 registered DBS trials. In recent years,
there have been about 40 new studies entered per year. The
purpose of these studies has varied from large classical trials
for new indications to investigations focused on more novel
uses and protocols of DBS (e.g., mindfulness during DBS
to improve patient comfort). The majority of studies have
been observational or early phase studies, with less than 10%
being interventional phase III-IV trials. Approximately 60%
of studies addressed the use of DBS for movement disorders,
with other areas of interest including psychiatric conditions
(e.g., obsessive-compulsive disorder, depression, etc.), cognitive
disorders (Alzheimer’s disease, non-Alzheimer’s dementia, etc.),
pain (e.g., headache, neuropathic pain), epilepsy, and others (e.g.,
tinnitus, lower urinary tract symptoms, etc.).
At present, 28 cerebral targets are utilized in DBS according
to this registry. These targets (inclusive of multiple sites being
used to treat the same disorder) included: PD [nucleus basalis
of Meynert, STN, GPi, ventral intermediate thalamic nucleus,
pedunculopontine nucleus (PPN)], depression (subgenual
cingulate gyrus, habenula, medial forebrain bundle, inferior
thalamic peduncle, ventral capsule/ventral striatum, nucleus
accumbens and anterior limb of the internal capsule;), and
obsessive-compulsive disorder (medial thalamus, inferior
thalamic peduncle, ventral capsule/ventral striatum, nucleus
accumbens, anterior limb of the internal capsule, bed nucleus
of the stria terminalis and the STN; Budman et al., 2018; Lee
et al., 2019). Nearby targets for the same disorder often may
be no more than a few millimeters apart. As the number of
disorders and brain targets under investigation continues
to expand, improved neurosurgical targeting accuracy and
current steering will be required to better define these
targets and to delineate nuclei vs. pathway stimulation. As
neurosurgical targeting becomes increasingly precise (and
‘‘personalized’’), direct comparisons using crossover study
designs will better inform the field. Advances in research and
technology in the field of DBS might allow not only treatment
of new disorders but also improve our understanding of the
pathophysiological mechanisms of neuropsychiatric conditions
and exploration of novel DBS targets using invasive and
non-invasive approaches.
Emerging DBS Targets in Motor Disorders
PPN DBS continues to be investigated for its role in
the freezing of gait in PD. Interest is driven largely by
the PPN’s documented relationship to the mesencephalic
locomotor region. Variability in PPN DBS outcomes has
been attributed to electrode targeting, patient phenotype,
outcome measure, and duration of benefit (Thevathasan
et al., 2018). As regards electrode targeting, a recent study
summarized PPN anatomy and targeting terminology and
noted domains of uncertainty that require further investigation
and elaboration (Hamani et al., 2016). Outcome measures
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have previously included the UPDRS as well as the use
of questionnaires that specifically assess gait and freezing.
While these are certainly valid, viable and of value, we
opine that employing objective measures will likely facilitate
the most useful and reproducible approaches. However,
procedures used and data gained in gait laboratories may
not represent real-world environments, and this variability of
such environmental circumstances may be a critical factor
for inducing freezing of gait. Indeed, many patients do not
freeze (or display improvement of freezing) when in laboratory
settings. Hence, reproducibility under laboratory conditions
(i.e., efficacy) may not be a reliable measure—or predictor—of
real-world effectiveness.
As well, it is important to note that the current state
of knowledge on PPN DBS is derived from relatively small-
scale studies, and there remains much room for continued
(and broadened) investigation. For example, a single case of
cyclical PPN DBS (DBS turned off overnight) provided extended
benefit beyond that produced by non-cyclical PPN DBS (Stefani
et al., 2013). Other approaches, including dual stimulation or
dual-frequency stimulation of the STN and substantia nigra
pars reticulata (SNr) for resistant axial motor impairment as
well as spinal cord stimulation (Weiss et al., 2013; Samotus
et al., 2018; Valldeoriola et al., 2019) and adaptive loop DBS
has also been undertaken. Additional small uncontrolled studies
are exploring other targets for refractory tremors including the
caudal Zona incerta and the centromedian and parafascicular
nuclei of the thalamus. Combined PPN and caudal zona incerta
stimulation, stimulation of the Centromedian and Parafascicular
nuclei of the thalamus, and extradural motor cortex stimulation
are other targets currently being investigated for themanagement
of refractory axial symptoms in PD (Anderson et al., 2017).While
outcomes are promising, these (and additional) approaches will
require further study.
Using Multiple DBS Targets
Electrodes with multiple contacts may be used to simultaneously
reach many targets oriented along a dorsal-ventral axis.
Exemplary cases have included stimulation of the STN and
thalamus for mixed PD and ET-like action tremor (Baumann
et al., 2012), as well as the aforementioned STN and SNr
stimulation for gait and balance. Different electrode designs, such
as the Boston Scientific 8-contact device (spanning 1.5 cm) may
provide greater flexibility for simultaneously targeting multiple
sites for DBS. This device could enable the option to stimulate
the SNr, STN, posterior subthalamic region, and thalamus with a
single trajectory.
A small double-blind, crossover study is currently in progress
to test stimulation at many of these sites. Additionally, it
is known that both GPi and globus Pallidus externa (Gpe)
DBS may be beneficial for patients with PD (Vitek et al.,
2004). Therefore, it may be of value to synergistically target
the GPi and GPe, and double stimulation may be more
beneficial than stimulation directed to either target alone.
Further, a trial is currently underway that employs simultaneous
targeting of GPi and the nucleus basalis of Meynert to
affect motor and cognitive symptoms in PD (NCT02589925).
Novel electrode designs may also prompt further innovation
in multiple targeting approaches. The trend in the field
has been slowly moving toward the use of multiple DBS
targets. These can now be accessed with a single DBS device,
and we believe that such developments will afford greater
possibility, accuracy, and effectiveness for targeting multiple
signs, symptoms, and dimensions of a variety of neuropsychiatric
(and other) disorders.
A Randomized Controlled Trial of
Personalized Adaptive-Loop DBS to
Ameliorate Treatment-Resistant
Depression
Major depression is a leading cause of disability worldwide.
As well, not all patients respond to pharmacological standard
of care interventions. Thus, we believe that those patients
resistant to current standards of care might benefit from the
use of novel neurotechnologies like DBS. However, randomized
control trials of using continuous DBS of pre-selected brain
locations to treat major depression, while relatively efficacious,
did not yield statistically significant results (Kisely et al., 2018).
Difficulties in treating depression with DBS may be related
to the complex and heterogeneous nature of this disorder.
A personalized aDBS approach that takes into account inter-
individual differences could address these challenges. We have
designed a 3-stage randomized controlled trial for intervention
against treatment-resistant depression (i.e., the PRESIDIO trial)
that will test the feasibility, safety and initial efficacy of
personalized adaptive-loop DBS with the NeuroPace Responsive
Neurostimulation (RNS) System (NCT04004169). Enrollment
will include 12 adults with severe treatment-resistant depression
who have been unresponsive to four trials of antidepressant
medication and psychotherapy.
During the first stage of the study, subjects will undergo
temporary implantation of electrodes and will be tested for
biomarkers and conduct stimulation endpoints in order to guide
target selection. In the second stage, the NeuroPace RNS System
will be implanted with lead placement guided by results achieved
during stage 1. Subsequently, the short-term and long-term
efficacy of personalized adaptive-loop DBS treatment will be
examined. The primary outcome measure will be a change in
the Montgomery-Asberg Depression Scale (MADRS) score after
6 weeks of treatment stimulation compared with 6 weeks of sham
stimulation. Safety will be monitored and recorded throughout
the trial. This trial will provide a first-time opportunity to obtain
direct recordings of neural networks involved in—and focal to
the treatment of—treatment-resistant depression. This trial may
enable the identification of quantitative markers of depression
and afford an understanding of their dynamics.
Stereoelectroencephalography for DBS
Targeting in Pediatric Patients
The targets of DBS treatment of pediatric secondary dystonia
vary across patients. The current standard of care to confirm
DBS targets in secondary dystonia involves intra-operative
microelectrode recordings, which entail waking the patient
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during surgery, and therefore necessitates anesthesia without
intubation. However, there are children who are unable
to tolerate this standard technique because of hyperkinetic
dystonic movements and/or airway issues. To overcome this
challenge, we have developed a novel 3-stage neuromodulation
approach to determine clinically effective DBS targets
(Sanger et al., 2018). At stage 1, patients are implanted with
stereoelectroencephalography (SEEG) electrodes (Adtech
mm16c) in ∼10 potential targets for 5 days of testing and
observation. This testing involves single-unit recordings,
confirmation of locations with peripherally- and intracortical-
EPs, identification of the therapeutic window (efficacy and
side effects), and the effect(s) of stimulation on specific tasks.
These data can then be used to determine whether to proceed
with the second stage (i.e., implantation of DBS leads) and
third stage (i.e., implantation of the pulse generator). Typically,
approximately 50% of patients with secondary dystonia
who undergo DBS show clinically relevant improvement. In
comparison, 88% of subjects showed improvements on dystonia
scales (Burke-Fahn-Marsden Dystonia Rating Scale, an average
improvement of 10 points), and no subjects had worsening
of signs and symptoms when utilizing this neuromodulation
approach. Overall, this approach was well-tolerated, but there
was a significant microlesion effect that seemed to resolve within
a week, and this effect may limit the number of thalamic leads
to six. Moving forward it will be important to focus on smaller
electrodes that may induce smaller microlesions and a simplified
conversion to permanent leads.
Use of SEEG for Early Evaluation of Novel
Targets and Indications
Classical DBS targets have primarily been based on decades
of clinical experience using therapeutic lesions. Advancements
in neuroimaging, recording electrodes and overall insight to
the node and network function in the brain (both in health
and disease) have prompted consideration and exploration
of new targets for DBS to treat an expanding number of
pathologies. However, new targets and indications lack the
validation necessary to move from promising preclinical studies
to rigorous clinical trials. One possible means to address and
close this gap between preclinical studies and clinical trials
is SEEG. As discussed above, SEEG involves the temporary
(<3 weeks) implantation of multiple depth electrodes with
an array of contacts in different deep brain regions. SEEG
electrodes are similar in size and impedance to traditional DBS
electrodes, can be implanted into many regions simultaneously,
and can utilize externalized stimulators to test novel waveforms
and adaptive-loop paradigms. This technique has been used
in epileptic patients since the 1960s to record the onset and
early spread of seizures (Youngerman et al., 2019). This history
of being a well-tolerated and safe technique affords SEEG a
particular advantage when considering its use in other protocols
and paradigms. Still, it is important to note that the use of SEEG
in epilepsy patients may not provide direct comparative value for
the use of this technique with DBS.
Yet this too provides a window of opportunity to assess the
efficacy, effectiveness and relative research and clinical value of
SEEG in tandem with DBS. Toward such ends, the SEEG may
be used: (1) for research in patients without epilepsy; (2) with
implantation of other (additional) electrodes for studying effects
in recording and stimulating brain regions of patients with
other (non-epileptic) disorders; (3) for clinical purposes; and
(4) to modify the trajectory of clinical electrodes. Evidently,
there are ethical issues that must be considered when deciding
upon an implantation intent and strategy (e.g., institutional
review board (IRB) approval, informed consent, FDA exemption,
and scientific rationale rigor). Some examples of recent use
of SEEG with DBS include treatment of tinnitus; developing
brain-computer interfacing of the primary motor cortex; DBS
of the dorsal hippocampal commissure for treatment of mesial
temporal lobe epilepsy; DBS of the hypothalamus for treating
hypertension; theta burst stimulation/of the fornix region for
treatment of post-traumatic memory loss; and DBS of the rostral
cingulum bundle for treatment of bipolar disorder. Thus, with
proper approval, SEEG can provide a powerful tool to evaluate
short-term stimulation of novel DBS targets, and in such ways,
may be instrumental to the discovery of new methods and
applications of DBS.
NEW DEVELOPMENTS IN OPTOGENETICS
AND DBS
Thalamocortical (TC) Physiology in Autism
To understand how different gene mutations lead to a common
behavioral phenotype, it is necessary to gain insight into the
ways that diverse genetic etiologies converge at the level of
neuronal circuit physiology, and how changes in these circuits are
involved in behavior. Previous studies have identified prefrontal
circuits that are operative in symptoms and signs of autism
spectrum disorder (ASD; Cheon et al., 2011; Kalmbach et al.,
2015; Demetriou et al., 2018; Brumback et al., 2018; Maximo
and Kana, 2019). The integrity of the reciprocal circuit, from
the thalamus to the prefrontal cortex (PFC), is required for
many prefrontal-dependent behaviors (Parnaudeau et al., 2018).
However, the ability to target these reciprocal prefrontal-TC
circuits for neuromodulation is hampered by the lack of
understanding of thalamic cell types (Rikhye et al., 2018).
Apropos of this paucity of understanding, our current work
focuses on single-cell electrophysiology of specific mediodorsal
(MD) thalamic neurons that provide ascending input to the PFC,
with emphasis upon the ways that these neurons are affected
in a model of the autism-associated Fragile-X syndrome (FXS).
Using a mouse model, retrograde tracers were stereotactically
injected into the medial PFC to fluorescently label neurons in the
thalamus that project to PFC. Using acute brain slices, whole-cell
patch-clamp recordings were taken from visually-identified TC
neurons in MD. It was observed that MD→mPFC neurons
divide into two populations based on the presence or absence
of a prominent conductance mediated by hyperpolarization and
cyclic nucleotide-gated (HCN) channels (‘‘voltage sag’’). It was
hypothesized that these two populations (‘‘High Sag’’ and ‘‘Low
Sag’’) may be globally affected in autism models, or alternatively,
that one population would be selectively impacted. To test this,
recordings from these two populations of MD→mPFC neurons
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were taken in acute brain slices from FXS mice and control
littermates. It was observed that in FXS mice, High Sag neurons
were hypoexcitable; whereas Low Sag neurons were relatively
unaffected. This mirrors findings of abnormal excitability in
High Sag mPFC→MD neurons as previously described by
our group and others. Ongoing studies aimed at obtaining
in vivo recordings of LFPs and optogenetic manipulations will
evaluate how differences in High and Low Sag neuron physiology
influence TC oscillations and behavior. It is hoped that localizing
symptoms and signs to specific circuits will help to create circuit-
level therapies regardless of the genetic cause of the disorder.
Neural Circuit Mechanisms of Memory
Retrieval: Toward Mechanistic Insights and
Therapeutic Targets
A current approach to understanding memory involves
activating populations of cerebral neurons in order to
examine how specific circuits and networks interact with
the hippocampus to form, store and retrieve information. Our
studies are aimed at identifying frontal brain areas and networks
that could contribute to top-down (i.e., cortico-hippocampal)
vs. bottom-up (i.e., Hippocampo-cortical) memory processing.
Such top-down networks are indicative of storage pathways that
are relatively independent of acquisition pathways, and these
pathways could prove to be viable targets for DBS-based therapy
for Alzheimer’s disease and/or Post-Traumatic Stress Disorder.
This technique involves injecting a retrograde virus to
the hippocampus to identify direct inputs, including a direct
prefrontal- -hippocampal pathway. Using tracer technology, it
was demonstrated that these inputs were monosynaptic, and
electrophysiological patch recordings revealed a prevalence of
direct short-latency excitatory transmissions (Rajasethupathy
et al., 2015). Optical activation of the prefrontal inputs
to the hippocampus suggested the existence of prefrontal
cortical mechanisms that could drive goal-directed memory
retrieval in the hippocampus. Further experiments using
in vivo calcium imaging of the hippocampus, paired with
optogenetic activation of prefrontal inputs elucidated that
behavioral training fortified hub neurons in the hippocampus
that exist within an otherwise uncorrelated neural ensemble.
These hub neurons were preferentially targeted by top-down
prefrontal inputs and appear to act as conduits to recruit
other domains of the memory network. These results suggested
that plasticity in the prefrontal cortico- hippocampal network
may contribute to PFC engagement of (the most recently
active) memory encoding cells to enable future rapid retrieval
of important memories. These insights into PFC-hippocampal
memory networks may be important to the development of
next-generation neuromodulatory approaches to learning and
memory acquisition, preservation, and retrieval.
Optogenetic STN DBS
The mechanisms underlying the therapeutic effects of STN DBS
for PD are still poorly understood. The anatomical heterogeneity
of brain tissue is such that DBS can modulate the activity of
multiple neuronal elements in the STN, as well as in surrounding
regions. Optogenetic techniques that enable cell-type-specific
activation allows assessment of the behavioral effects of selective
stimulation of STN local neurons and hyper direct pathway
axons (Gradinaru et al., 2009). Selective activation of STN
excitatory neurons is not effective for treating Parkinsonian
symptoms in the unilateral 6-OHDA lesioned rat model of PD
(Gradinaru et al., 2009). However, this conclusionmay have been
influenced by the slow response kinetics of channelrhodopsin-2
(ChR2) precluding generation of the regular high rate activity
required for symptom relief (McConnell et al., 2012, 2016), and
it remained unclear whether STN local cells contributed to the
therapeutic effects of DBS.
Therefore, we re-examined the role of STN local cells in
mediating the symptom-relieving effects of STN DBS using a
much faster opsin: Chronos (Klapoetke et al., 2014). Optogenetic
stimulation of Chronos-expressing STN cells at 130 Hz reduced
pathological circling behavior, in contrast to results obtained
using the much slower ChR2 opsin. Furthermore, optogenetic
DBS of STN with Chronos was strongly dependent upon
stimulation rates: high-frequency DBS (75, 100, 130 pps)
relieved ipsilateral turning; while low rates (5 and 20 pps)
were ineffective. In addition, optogenetic STN DBS at 130 pps
corrected the bias to use the unimpaired forepaw in forelimb
stepping; while the low rate (20 pps) DBS was not effective.
These results indicated that direct optogenetic stimulation
of STN neurons was effective in treating the symptoms
of parkinsonism in the 6-OHDA lesion rat, provided that
a sufficiently fast opsin was used. These findings highlight
that the kinetic properties of opsins can strongly influence
the effects of optogenetic activation/inhibition, and therefore
must be considered when employing optogenetics to study
neural stimulation.
HOLOGRAPHIC DEEP BRAIN
STIMULATION; THE COMBINATORY USE
OF MIXED, AUGMENTED, AND VIRTUAL
REALITY AND DBS
Virtual reality (VR) and augmented reality (AR) are increasingly
being utilized for research and clinical applications. Technologies
such as the Oculus VR system, the Microsoft Hololens, and
other VR and AR systems enable enhanced visualization of
neuroanatomy within a 3-dimensional (3-D) environment.
Currently, most neuroanatomy has been presented in
2-dimensional (2-D) images utilizing generic axonal pathways
that have been derived from textbook illustrations. This approach
has not been sufficiently accurate to understand the complexity
of axonal pathways and the effect of stimulation as applicable
to deep brain neuromodulatory approaches. The Microsoft
Hololens was first demonstrated in 2013. The Hololens enabled
researchers to render 3-D visualization and allowed multiple
users to interact with a model while maintaining interaction with
each other1.
The first step in developing an accurate 3-D model of an
axonal pathway atlas for DBS is to reconstruct tractographically-
1https://case.edu/hololens/
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based pathways in basal ganglia. Layers of cortical surface
rendering and vasculature can be added to the holographic
3-D model to increase the interactivity within and between
users (Petersen et al., 2019; Supplementary Figure S5). These
components allow neurosurgeons to better understand the
different pathways within, between, and across brain structures.
After the structures and axonal pathways are constructed, users
can adjust the electrode trajectory to display different DBS
lead insertions. Combining the trajectory and volume of tissue
activation facilitates the visualization of structures and pathways
that potentially would be activated by stimulation. This method
can be used to enhance patient-specific surgical planning.
Holographic visualization provides a new medium for creating
axonal pathway models that we believe will certainly advance the
scientific understanding and clinical utility—and value—of DBS.
Using VR for Patient Engagement
The recent technological advancement coupled with the
increased presence of social media has afforded growing
opportunities for engaging and interacting with neurosurgical
patients. In some circumstances, we believe that it is important
to initiate the engagement of patients prior to commencing
clinical care. To maximize pre-clinical patient engagement, we
have developed informative social media and/or online websites
that use AR simulation to provide high fidelity examples of
prior surgical cases (Steinberger et al., 2020). This process
allows patients to view and acquire gain knowledge of surgical
procedures prior to the consultation, which can fortify patients’
level of familiarity and comfort with the procedures to be
implemented. Of course, it is important to obtain patient
consent if and when sharing information on social media.
As well, when sharing information using simulation for social
media engagement, caution should be exercised to avoid any
patient identifiers.
The surgical team should explain how the AR simulation
is created and how the surgical plan will be based upon the
simulation. Surgical Center, an FDA approved surgical planning
software, is currently being used for all AR simulations at
the Mt. Sinai School of Medicine. The software includes 3-D
modeling of the brain, a patient-specific navigation system, and
a non-distracting heads-up display. Using these technologies,
surgeons can develop a tailored consultation based on types
of surgery within the nervous system. AR simulation is
increasing patient satisfaction and retention. For example, after
using AR for patient consultation, patient satisfaction with
(i.e., -Press Ganey Scores), and confidence in the surgical
team was shown to increase. A pilot study at Stanford studied
the effect of neurosurgical VR services on patient satisfaction
and revealed that overall more positive evaluations of surgical
experiences (Collins et al., 2018). Currently, a research study
is underway to assess the effect(s) of AR simulation on several
metrics of neurosurgical patient satisfaction due to AR. While
contributory to an increased appreciation for, and relative value
of the potential uses and benefit of AR-based neurosurgical
simulations, there is also a need for large-scale randomized
trials to further explore patient engagement, experience and
satisfaction when using this technology.
Using VR With Local Field Potential
Acquisition
Beyond surgical planning and patient orientation, VR can be
used to simulate real-world environments while simultaneously
studying neural signals. One problem with current methods for
measuring and/or modulating brain activity has been movement
artifacts that may obscure the signal. In combination with
wireless chronic recording and stimulation devices such as
Neuropace RNS, the Medtronic Percept, and the Medtronic
RC+S, VR has facilitated the development of simulated tasks that
are naturalistic and therefore more ecologically valid in order
to study the neural signals relevant to DBS therapies in awake
behaving humans (Collins et al., 2018).
To accomplish this goal, Topalovic et al. (2019) have
developed a wireless control and synchronization system for
the Neuropace RNS system using a Raspberry Pi equipped with
network synchronization. This is a lightweight portable system
including the Neuropace programmer and accessory that can
communicate with the neurostimulator. While working on the
synchronization system, a challenge arose due to telemetry-
induced artifacts in scalp EEG. Although the artifacts could
be filtered from the signal, it was more beneficial to utilize a
custom USB switch to turn off telemetry after the recordings
start. This procedure prevented injecting artifacts into the neural
recordings. Layered atop the synchronization system and VR
was the latitude to add external biometrics using eye-tracking
and inertia sensors to capture the comprehensive behavioral data
simultaneously during neural recordings.
This system is not specific to the Neuropace RNS system, and
it can be adjusted for use in another system by simply connecting
the sensing program to a Raspberry Pi interface. This procedure
allows for full integration. We have found this system to be
capable of integrating VR and LFPs. Additionally, Aghajan et al
recently published their work using VR/AR in combination with
Neuropace RNS to study spatial memory (Aghajan et al., 2017).
This platform enables novel methods to study intracranial EEG
activities during freely moving tasks with naturalistic behavior
under experimental control.
ADVANCES IN COMMERCIAL
TECHNOLOGY AND FUTURE DIRECTIONS
Towards Adaptive Therapies in DBS
In recent years, DBS technology has evolved to improve patients’
clinical outcomes and experience and interactions with the
device. There are several mechanisms that can be employed
to improve patient results, including calibration (optimizing
parameters for specific patients and symptoms), lead localization,
and the use of adaptive (closed-loop) technology. We opine
that the improvement of aDBS applications will be particularly
important—and necessary—to bridge this technology from
research into clinical practice.
aDBS uses a marker to potentially trigger multiple stimulation
parameters to improve the outcomes of stimulation. An example
of this technology is provided by a Medtronic system, the
Percept PC+S, that is capable of aDBS approaches for both
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research and clinical applications. The device offers state-of-
the-art stimulation capabilities and includes a sensing engine
for recording during stimulation. The device was designed to
offer flexible configurations and real-time recording with longer
telemetry distances. The device is smaller than other units and
has longer battery life. Utilizing the PC+S real-time sensing
and controlling capabilities allows aDBS applications. However,
iterative evidence of efficacy will be required to clear this system
for clinical use.
Previous approaches in aDBS focused on disease indications
(e.g., PD, essential tremor, dystonia, epilepsy, Tourette
syndrome, etc.,) For each indication, the initial approach
has been to identify a signal of interest and to create control
parameters (i.e., how the sensing signal triggers the stimulation).
Controller classes based on amplitude, triggered response,
desynchronization patterns, and other settings can be used
group or categorize applications. The goal of centering use on
controller classes is to develop broad evidence of safety and utility
in order to expedite broader access to these technologies without
the limitations incurred by simply using narrow disease-based
applications or signals of interest.
Directional DBS: Looking Back to Look
Ahead
Previous DBS Think Tanks have identified key limitations
with the technologies available at the time. Technologies
under development were evaluated for their potential to serve
unmet needs, and for each experimental approach, the most
pertinent unknowns were identified. For example, the use of a
segmented lead to provide ‘‘directional’’ or axially-asymmetric
stimulation fields was one such development that was assessed
in prior Think Tanks (Deeb et al., 2016; Ramirez-Zamora
et al., 2018). In this regard, three important questions were
posed: (1) would dDBS achieve a wider therapeutic window?;
(2) how would stimulation through smaller, higher impedance
electrodes affect power consumption?; and (3) how many
segmented contacts would need to be activated, and would
current fractionalization technology (e.g., multiple independent
current controllers or temporal fractionalization through multi-
stimulation sets/ interleaving) be required to achieve effective
‘‘steering’’ of electric fields?
The Abbott-sponsored study of directional vs.
omnidirectional (conventional) stimulation (PROGRESS)
provides the first high-quality evidence to address these
clinically pertinent questions. This study prospectively enrolled
234 patients with STN DBS across 32 actively enrolling sites
in Europe, the United States, and Australia. The primary
outcome measure, therapeutic window, was evaluated in a
randomized, double-blinded manner, 3 months after study
enrollment. Secondary endpoints (patient and physician
preference, on-meds UPRDS III) were evaluated in a sequential
single-arm cross-over design: all patients received 3 months of
omnidirectional stimulation followed by 3 months of directional
stimulation. A performance target of 60% of patients with
gain in therapeutic window on at least one side with dDBS
was defined—in agreement with the European regulatory
agency—as the superiority end-point. Primary endpoint data
were available for 202 patients at the time of this year’s
(2019) Think Tank. Of those evaluated, 90.6% of patients
achieved a wider therapeutic window with dDBS (with a mean
40% gain in therapeutic window), thereby surpassing the
superiority endpoint. Additionally, 86.6% of patients achieved
a superior therapeutic window with the activation of a single
segment compared to omnidirectional stimulation.
Directional stimulation achieved similar benefits at
significantly lower therapeutic current strength (39% lower
compared to conventional stimulation), which can have a
meaningful positive impact on IPG lifespan. The programming
approach prescribed as part of the protocol: prioritizing single
segment activation and small step size for amplitude increments
during a monopolar review, may importantly contribute to
these results.
Focusing on Improving DBS Outcomes
Boston Scientific has been developing technologies to improve
DBS outcomes and accelerate programming. One of these
products, developed with Great Lakes NeuroTechnologies,
is Kinesia StimPoint: a tablet-based solution for augmented
programming. This software presents a 2-D plot (stimulation
location vs. amplitude) used to test, score, and view the clinical
outcome of stimulation. Scores can be entered manually, or
automatically using integrated accelerometer-based objective
measures. This process updates the 2-D plot to reveal a
stimulation response surface, and an algorithm suggests next
settings. Boston Scientific is working to add support for
directional leads to StimPoint. Programming may also be aided
using patient imaging data paired with 3D stimulation models
as in the Guide XT software, developed with BrainLab. When
available, the combination of surgical, imaging, and stimulation
response priors with real-time clinical response may further
assist programmers.
Prior experimental and modeling studies have demonstrated
that using hyperpolarizing or depolarizing pre-stimulation pulses
affects stimulation outcome, especially between fibers of differing
(bio)physical properties (Grill and Mortimer, 1996). Simulation
of microelectrode stimulation also suggests selectivity between
cells and fibers may be possible (Grill and McLntyre, 2001).
DBS experiments suggest that changes in the stimulating pulse
results in changes in response (Akbar et al., 2016). Boston
Scientific has developed research programming software which
unlocks additional stimulator capability, without the need to
alter device firmware. In particular, the software can control
the polarity, amplitude, and pulse-width of additional active
stimulation pulses, adding a pre- and post-pulse to the existing
stimulation pulse. These pulses can be distributed across the lead
electrodes (e.g., a pre-pulse to E1, stimulation to E1 and E2, and a
post pulse to E2). Boston Scientific stimulators support combined
pulse configurations of up to 12 active phases, enabling clinical
testing of pulse shapes previously explored in computational
models (Foutz and McIntyre, 2010).
The INSHAPE DBS project, led by KU Leuven, has tested
various non-commercial pulses in PD and ET patients in a
randomized double-blind crossover design using the above
system. For this study, a sensing component was added by
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including EPs recorded with EEG, and further testing will be
performed in an expanded cohort in the chronic condition.
The project has investigated 12 different stimulation pulses,
combining cathodic, anodic, and biphasic pulses with additional
hyperpolarizing pre-pulses of a low,medium, and high amplitude
with pulse widths of 120, 240, and 360 µs. Therapeutic
window was measured between the minimum current to
observe a therapeutic response and the maximum current before
observing any side effect. From preliminary data in 4 patients,
these investigators found that the different combinations of
stimulation pulses had distinct effects in the therapeutic window
and that this effect was patient-specific. Additional research
will be required to refine this technique toward improving
clinical outcomes.
NEUROETHICAL, LEGAL, AND
SOCIO-CULTURAL ISSUES OF DBS
As this report, and proceedings from prior Think Tanks
illustrate, DBS, like many domains of current and emerging
neurotechnology, is advancing, in large part, because of
increasingly sophisticated engineering, and expanding
knowledge as well as an enhanced understanding of neural
systems (Gunduz et al., 2015; Deeb et al., 2016; Rossi et al., 2016;
Ramirez-Zamora et al., 2018, 2019). These advances are fostering
growing consideration of DBS for studying and treating a
broadening scope of neuropsychiatric disorders. Moreover, DBS
research and clinical use are becoming ever more international,
as several countries are dedicating considerable financial
resources to large-scale neuroscientific and neurotechnological
initiatives. The field is collaborative and competitive; and
both collaboration and competition can evoke asymmetries
in technological capability, focus and scope of research, and
provision and access to interventions (Martin et al., 2016; Becker
et al., 2017; Giordano, 2017). These asymmetries can—and likely
will—occur both within nations (e.g., as reflective of differing
economics, insurance coverage, etc.,), and between nations
(i.e., in light of distinct cultures’ economies, norms, and values,
philosophies, ethics, and laws).
Thus, while some ethical issues can be similar or identical
(e.g., risks of neurosurgery; inherent uncertainties of new
technology), others may not (Martin et al., 2016; Becker
et al., 2017). As we have noted, even fundamental ethical
concepts (e.g., meanings, value, and questions about autonomy,
as affected by DBS such as those described below) can be
viewed and regarded through differing cultural lenses (Giordano,
2016). Laudably, several intra- and multi-national groups have
committed resources to address the ethical-legal and social issues
generated by DBS research and use (for example, the efforts of
the United States’ National Institutes of Health; and Asociación
Mexicana de Neuroética, as reported in this article, as well as
numerous others).
This is vital, given that the internationality of brain science
enterprises would require any authentic neuroethics to be
insightful, relevant, and responsive to issues arising in and
from the development and applications of DBS—and other
neurotechnologies—on the global stage (Rossi et al., 2014;
Ramirez-Zamora et al., 2018). To effectively approach these
challenges—and opportunities—it will be important to establish
some international forum for the iterative exchange of ideas (of
currently committed programs, and newly emerging projects in
neuroethics), that remains apace with worldwide developments,
capabilities, and limitations of neuro-engineering and the
social sphere.
The IEEE Brain Initiative Neuroethics
Program
Toward such ends, the Institute of Electrical and Electronics
Engineers’ (IEEE) Brain Initiative Neuroethics Subcommittee is
engaged in a multi-year effort to identify current international
trends in neuro-engineering; define uses in various contexts
and practices; describe ethical-legal and social implications,
issues, questions and problems; and develop guidelines for
their responsible address. Bringing together subject matter
experts in engineering, anthropology, philosophy, ethics and law
(see www.braininitiative.org/alliance/ieee-brain), the project is
creating an open-access, web-based (and print) platform that
enables interactive discourse and ongoing updates as pertinent
to developments in the field—and its spheres of application.
Importantly, the project aims to develop: (1) consensus
and dialectic among share- and stake-holders in the field;
and (2) public visibility and awareness of the process. The
project, which began in summer 2018 is aiming toward
completion by mid/end-2021 (for more detailed information, see
www.braininitiative.org/alliance/ieee-brain).
To be sure, the use of DBS, like any therapeutic approach,
is aimed at providing maximum benefit for the good of those
patients in need. As DBS gains in both technologic sophistication
and relative popularity, wemust be cognizant that the use of these
technologies and techniques uphold patients’ values and goals.
These concerns call special attention to evaluating DBS and its
outcomes, incorporating neuroethical assessment and guidance
into research, and understanding the use of DBS in and across
international contexts of use.
Control, Personality, and Neuroethical
Issues in the Use of DBS for PD
Gisquet (2008) have claimed that DBS is a disruptive experience
for some patients due to the associated loss of control of
the illness and of one’s life, and the possibility of undesired
personality changes incurred by the use of this technology.
These concerns generated considerable conceptual neuroethical
discourse, however, most publications addressing this topic were
not based on empirical data (Frederic Gilbert and Ineichen,
2018). Thus, efforts are underway to employ empirical methods
to re-examine assertions that DBS results in diminished control
and undesired personality changes. Initial studies focused on
DBS for PD systematically solicited patients’ major symptom-
reduction and functional expectations and goals for DBS surgery.
Changes in symptoms and patients’ perception(s) of control
were prospectively assessed at baseline, 3 months post-op, and
6 months post-op. It was found that overall, DBS significantly
improved patients’ symptoms and personal goals and that these
outcomes were highly meaningful and valuable to them.
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Interestingly, despite conversations with multiple team
members regarding expectations, symptoms that typically do not
respond well to DBS (i.e., non-motor symptoms) were among
those most cited as symptom-relevant goals (Kubu et al., 2017).
Patients’ underlying motivations to pursue DBS were primarily
related to larger life goals including relationships, avocational
pursuits, and work. Additionally, patients’ sense of global control
of their life significantly increased after DBS, whereas their desire
to control their device decreased as patients developed increasing
trust in the treatment team and their expertise. Importantly, these
initial studies revealed that existing clinical measures do not fully
capture patients’ goals and motivations. This is a critical issue
for assessing patient-centered care, the effectiveness of DBS, and
the clinical team’s performance (Kubu and Ford, 2012; Kubu
et al., 2017, 2018). Furthermore, patients’ primary treatment
goals changed after DBS, calling into question the idea of how
these expectations may change over time, and what this infers
for consent.
Current studies are exploring patients’ and family members’
perspectives and experiences of the preservation of their most
valued personality characteristics at different stages of PD and
over the course of DBS, using a cohort of patients with PD
diagnosed less than 1 year prior, diagnosed within 5–7 years
prior, and patients approved for DBS. Preliminary results reveal
that standard personality measures do not comprehensively
assess what matters most to patients. Furthermore, patients
retrospectively reported an average decline in valued personality
characteristics over the course of PD across all three cohorts.
However, patients who are candidates for DBS were significantly
more likely to anticipate future gains in valued personality
characteristics (closer to their premorbid level), whereas patients
who are not candidates for DBS anticipated continued losses of
valued personality characteristics over time. Finally, DBS was
associated with personality ratings closer to reported historical
scores and an increase in global control. In sum, these data
refute some of the claims that DBS causes undesired personality
changes, provides empirical evidence of what clinical goals and
outcomes are most important to patients and families, and these
findings highlight the need to develop clinical measures that are
more patient-centered and more accurately address and reflect
individual patients’ values.
Updates on the NIH BRAIN Initiative in
Neuroethical Issues
As developments in technology and neuroscience introduce
novel ethical challenges in research and clinical care, a
more contemporary definition of the foci and functions
of neuroethics—as a field and set of practices—is needed.
Advances in neurotechnology research, development and
use make it important to consider emerging questions and
implications that such progress foster for research participants,
family members, researchers, and the community-at-large.
To address these questions and develop a roadmap for future
inquiry in neuroethics, the National Institutes of Health (NIH)
established an advisory committee under auspices of the Brain
Research through Advancing Innovative Neurotechnologies
(BRAIN) Initiative. In recognizing the need and value
of supporting neuroethical inquiry and address, the NIH
has begun to fund research and training projects through
a variety of funding mechanisms (e.g., R01s, F32s), and
administrative supplements to embed ethicists into BRAIN
Initiative-supported research.
As we use novel neurotechnology in clinical trials, several
guidelines have been developed, with safety being the most
important factor to consider. In this regard, researchers
should ensure informed consent processes are attentive towards
psychosocial risks (i.e., changes in self-identity, effects of research
interventions on interpersonal relationships, and potential shifts
in patient values), and should include detailed protocols that
address end-of-trial and post-trial responsibilities relevant to
physical and psychological risks that may be incurred at
post-study follow-up. Additionally, researchers should include a
clinician on study teams to enable a better understanding of the
clinical implications of research undertaken.
Moreover, it will be important to foster public education to
create dialogs to communicate results of research in ways that
be broadly understood. Crucial to this pursuit is an awareness of
media influence on public views. To maximize the relevance and
generalizability of DBS research, it will be even more important
to include the public in neuroethical discourse. Finally, but
certainly not least, interdisciplinary collaborations should be
developed to more ably integrate neuroethical assessment
and guidance to ongoing research projects. We believe that
each and all of these steps will encourage attentiveness to
neuroethical dimensions of DBS research while supporting
training opportunities for the next generation of neuroethics,
researchers and clinicians.
Neuroethics in Global Context: The Use of
DBS in Mexico
Research and clinical use of DBS are expanding beyond the
developed world. This has prompted consideration if and to
what extent DBS is cross-culturally valid, pertinent and valuable.
As an exemplar, in Mexico, there are particular neuroethical,
legal and socio-cultural issues (NELSCI) that might shape
perceptions and evaluations of scientific and technological
tools and techniques (Karen Herrera-Ferrá et al., 2019). These
factors prompt consideration of proactive inclusiveness of
diverse ethnocultural contexts and factors (e.g., needs, values,
philosophies, beliefs and traditions) within and across countries,
in order to better understand various views (i.e., culturally-
framed cognition), specific local NELSCI, and attitudes that
could direct the use -or non-use- of advanced neurotechnology,
such as DBS. Comprehensive cultural competency could—and
should—be developed and fortified to provide complementary
reflections to enable more meaningful discourse, this will be
important to identify and increase clinical goals and benefits,
reduce burdens and harm(s), and in these ways, improve global
efforts to promote and sustain ethically sound translational—and
sensitively transnational—use of DBS.
Summary and Conclusions
The Seventh Annual DBS Think Tank addressed in the
most current: (1) commercially available technologies; (2) use of
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advanced technologies to improve clinical outcomes; (3) research
in neuromodulatory approaches to treating neuropsychiatric
disorders; (4) use and utility of complex neurophysiological
signals for advancing delivery of neurostimulation; and
(5) ethical issues arising in and from research and use of
DBS. Every year, the attendees of the DBS Think Tank are
asked to answer a questionnaire in which they position different
neurotechnologies on the Hype Cycle curve (Supplementary
Figure S6). Sixty participants responded, the vast majority
working at academic institutions and universities. The
weighted-mean experience in the field of neurotechnology
of the participants is 10 years. In the last year, DBS for
Parkinson’s disease and essential tremors remain at the
slope of enlightenment. Similarly, vagus nerve stimulator
(VNS) uses in obesity, rheumatoid arthritis, heart failure,
and stroke are at the technology trigger. Interestingly,
low-intensity focused ultrasound moved from technology
trigger to peak of inflated expectations, which corresponds
with its expanding applications. On the other hand, cochlear
implants dropped from the slope of enlightenment to the trough
of disillusionment.
These advances serve as both ‘‘markers of progress’’ and
challenges and opportunities for ongoing address, engagement,
and deliberation as we move to improve the functional
capabilities and translational value of DBS. It is in this
light that these proceedings are presented to inform the
field and initiate ongoing discourse. As consistent with the
intent, and spirit of this, and prior DBS Think Tanks, the
overarching goal is to continue to develop multidisciplinary
collaborations to rapidly advance the field and ultimately
improve patient outcomes. Our ongoing work remains dedicated
to these efforts.
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FIGURE S1 | Adaptive Deep Brain Stimulation (aDBS) relies on identifying unique
neurophysiological biomarkers using local field potentials (LFPs) at the cortical
(using Ecog) or subcortical (through the DBS lead) level to trigger and deliver
stimulation using an advanced sensing device (for additional details please refer to
main text).
FIGURE S2 | Example of a neuronal closed loop-DBS trial: upper panel
demonstrates fluctuation of subthalamic nucleus (STN) beta power within, above
and below the dual thresholds; lower panel demonstrates the DBS voltage
response. The insert highlights the decision events over a 1 s period, whether
DBS voltage increased (red triangles), stayed the same (no symbols), or
decreased (blue triangles). From Velisar et al. (2019) with permission.
FIGURE S3 | Real-time collection of local field potential to enable high accuracy
differentiation of clinical states for adaptive neuromodulation
(i.e., home environments).
FIGURE S4 | DBS evoked resonant neural activity (ERNA). (A) Applying
stimulation in the vicinity of the STN elicits evoked responses with decaying
oscillation morphology. Columns show the ERNA recorded at each electrode
when stimulation was applied to different electrodes (indicated by crossed axes) in
a person with PD. A 3D reconstruction illustrating electrode positions (green: STN,
blue: substantia nigra). (B) Normalized ERNA amplitude varies with electrode
position with respect to (w.r.t) the STN in people with PD (20 hemispheres tested;
box: 25th–75th percentiles; line: median; whiskers: range). ***p ≤ 0.001,
**p < 0.01, *p < 0.05. (C) Mean Unified Parkinson’s Disease Rating Scale
(UPDRS) improvement from stimulation after ranking electrodes within each
hemisphere according to ERNA amplitude (rank 1: largest ERNA; bars: standard
error). Results from 10 PD patients tested post-surgery (20 hemispheres). (D)
ERNA recorded in a person with PD at electrode implantation (blue) and under
general anesthesia 560 days postop (red). (E) ERNA frequency decreases with
increasing DBS amplitude (19 hemispheres tested). Red bars: p ≤ 0.001; yellow
bars: p < 0.05. (F) ERNA frequency correlates with relative beta band (13–30 Hz)
amplitude across the stimulation levels shown in (E; ρ = 0.58, p < 0.001). Colors
represent different hemispheres tested. Panels (A–D) from Sinclair et al. (2018)
with permission. Panels (E,F) from Sinclair et al. (2019) with permission.
FIGURE S5 | Illustration of Pathway Generation Process including:
(A) histological data from the Morel atlas, (B) histological data fitted to the CIT
168 brain atlas, (C) preliminary pathway trajectories were generated using
information from the MRI, histology, and previous literature, (D) mean trajectories
were generated for each pathway, (E) preliminary streamline bundles were
generated, (F) using the HoloLens system, these pathways were visualized,
discussed, and manually edited via holographic interactions with the
neuroanatomists and (G) finalized pathways. From Petersen et al. (2019)
with permission.
FIGURE S6 | Hype Cycle schematic representation. This Figure represents the
position of certain DBS-associated technologies at different stages of
development on the Hype Cycle curve (Fenn, 1999).
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